The New Delhi-based Ranbaxy Laboratories on Thursday announced that it had got approval from the US drug authorities to market a paediatric dose of its generic version of Augmentin, GlaxoSmithKline
Top Section
Explore Business Standard
Top Section
Explore Business Standard
Don’t miss the latest developments in business and finance.
The New Delhi-based Ranbaxy Laboratories on Thursday announced that it had got approval from the US drug authorities to market a paediatric dose of its generic version of Augmentin, GlaxoSmithKline
First Published: Mar 21 2003 | 12:00 AM IST